GSK Spin-Out NeRRe Raises £23m For NK Antagonists

New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.

NeRRe Therapeutics Ltd., which is developing a portfolio of neurokinin (NK) receptor antagonists for the treatment of conditions caused by neuronal hypersensitivity, has raised £23m ($28.4m) in an oversubscribed Series B financing round.

New investors Fountain Healthcare Partners, Forbion Capital Partners and Orbimed joined existing investors Advent Life Sciences and Novo A/S.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip